A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
DualityBio Inc.
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Elicio Therapeutics
Pfizer
Tempus AI
Elevation Oncology
Carisma Therapeutics Inc
Beijing Biostar Pharmaceuticals Co., Ltd.
UTC Therapeutics Inc.
Celldex Therapeutics
Klus Pharma Inc.
Xencor, Inc.
MacroGenics
SpeciCare
INSYS Therapeutics Inc